Name (Synonyms) | Correlation | |
---|---|---|
drug540 | Hydroxychloroquine plus Nitazoxanide Wiki | 1.00 |
drug1060 | Standard care Wiki | 0.45 |
Name (Synonyms) | Correlation | |
---|---|---|
D003141 | Communicable Diseases NIH | 0.11 |
D007239 | Infection NIH | 0.07 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.06 |
D018352 | Coronavirus Infections NIH | 0.05 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
In December 2019, Coronavirus infection (COVID-19) was identified as causing serious respiratory infection in humans. Initially COVID-19 was propagated by infected symptomatic individuals; currently the disease is disseminated by asymptomatic COVID-19 positive subjects. The prevalence of asymptomatic COVID-19 individuals is unknown. Due its physiologic immune suppression, pregnancy is a vulnerable time for severe respiratory infections including COVID-19. Limited information is available regarding the impact of COVID-19 in pregnancy and the prevalence and demographic profile of asymptomatic pregnant women. Despite reports of 15-20% positive COVID-19 tests in women admitted to Labor and Delivery, professional obstetric medical societies still recommend not prioritizing testing of patients who are asymptomatic. In the USA, COVID-19 symptomatic patients come predominantly from lower income, Black and Latino communities. No data are available on the rate and demographic distribution of asymptomatic positive COVID-19 pregnant women. To minimize the risk of inadvertent exposure asymptomatic individuals, recently our institution started COVID-19 testing in all admitted pregnant women. The investigators expect to gain knowledge on the impact of COVID-19 in pregnant women especially if asymptomatic and compare to other respiratory infections.
Description: Rate of asymptomatic pregnant women who test positive for COVID-19 at the time of hospital admission
Measure: Asymptomatic COVID-19 positive pregnant women Time: Through completion of the study, an average of 1 yearDescription: Rate of Hispanic pregnant women among those asymptomatic COVID-19 positive on admission
Measure: Asymptomatic Hispanic COVID-19 positive pregnant women Time: Through completion of the study, an average of 1 yearDescription: Rate of asymptomatic positive pregnant women who later will develop COVID-19 related symptoms
Measure: Follow up of asymptomatic COVID-19 positive pregnant women Time: Through completion of the study, an average of 1 yearDescription: Prevalence of COVID-19 positive newborns from infected mothers
Measure: COVID-19 positive newborns Time: Through completion of the study, an average of 1 yearDescription: Rate of COVID-19 positive pregnant women who develop respiratory / multi-organ complications requiring admission to Medicine or Intensive Care units / maternal death related to COVID-19
Measure: Severe COVID-19 disease in pregnant women Time: Through completion of the study, an average of 1 year